ZVRA

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a rare disease-focused biotechnology company that was founded in 2006 and was originally known as KemPharm, Inc. before rebranding in February 2023. The company is headquartered in Celebration, Florida, and has transformed from a prodrug development company into a commercial-stage rare disease therapeutics company. Zevra specializes in developing and commercializing treatments for serious medical conditions with high unmet needs, particularly focusing on central nervous system disorders and rare metabolic diseases. The company has successfully transitioned from a research-focused organization to one with multiple FDA-approved products and a growing commercial presence in the rare disease market.